Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameBiodlink-B
Stock Code01875
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一間臨床階段生物製藥公司,致力於開發及商業化創新型腫瘤藥物及療法,擁有針對各類癌症的綜合性在研腫瘤藥物組合,包括單克隆抗體、抗體偶聯藥物、溶瘤病毒藥物及特種腫瘤藥物(如脂質體藥物),並建立了集發現、產程開發、質量管理、臨床前及臨床開發、商業規模生產基地和銷售及營銷能力於一體的綜合平台。
Listing Date2019-11-08
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)蘇州市 蘇州工業園區 長陽街120號
Business Address (Hong Kong)香港 皇后大道東183號 合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.totbiopharm.com.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 6.55 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-10-29 to 2019-11-01
Global Offering Shares90,000,000 shares
HK Public Offer Shares (Initial)9,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)81,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO570,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share26.6%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 589,500,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 67 HK$ 439
2 lots 159 HK$ 1,041
2 lots 165 HK$ 1,081
5 lots 400 HK$ 2,620
11 lots 800 HK$ 5,240
17 lots 1,200 HK$ 7,860
23 lots 1,600 HK$ 10,480
29 lots 2,000 HK$ 13,100
35 lots 2,400 HK$ 15,720
41 lots 2,800 HK$ 18,340
47 lots 3,200 HK$ 20,960
53 lots 3,600 HK$ 23,580
59 lots 4,000 HK$ 26,200
119 lots 8,000 HK$ 52,400
179 lots 12,000 HK$ 78,600
358 lots 24,000 HK$ 157,200
477 lots 32,000 HK$ 209,600
537 lots 36,000 HK$ 235,800
597 lots 40,000 HK$ 262,000
1,194 lots 80,000 HK$ 524,000
1,791 lots 120,000 HK$ 786,000
2,388 lots 160,000 HK$ 1,048,000
2,985 lots 200,000 HK$ 1,310,000
3,582 lots 240,000 HK$ 1,572,000
4,179 lots 280,000 HK$ 1,834,000
4,776 lots 320,000 HK$ 2,096,000
5,373 lots 360,000 HK$ 2,358,000
5,970 lots 400,000 HK$ 2,620,000
8,955 lots 600,000 HK$ 3,930,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
11,940 lots 800,000 HK$ 5,240,000
14,925 lots 1,000,000 HK$ 6,550,000
29,850 lots 2,000,000 HK$ 13,100,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 2.99B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +225%

Valuation & Financials

Market Cap (at Offer Price)HK$ 4,018,500,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣268.3百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 80,100,000
Listing Expenses / Funds Raised~13.59%
Total Pre-IPO Investment186.0百萬美元

Financial Data

Unit: '000 RMB
Income Statement
Item 20172018
Revenue 51,60839,219
Cost of sales -4,242-5,980
Other income and gains, net 6,00011,808
Selling and distribution expenses -28,886-38,935
Administrative expenses -24,514-54,638
Operating profit -105,969-237,177
Net finance costs 193-1,677
Profit before tax -148,687-268,263
Income tax expense 00
Profit for the year -148,687-268,263
Profit attributable to owners -148,687-268,263
Balance Sheet
Item 201720182019-04
Cash and cash equivalents 24,581256,751
Trade and bills receivables 6,5009,694
Inventories 9803,105
Total current assets 87,974299,687
Total assets 364,057677,238
Total current liabilities 21,78775,139
Total liabilities 286,741861,716
Total equity 77,316-184,478
Equity attributable to owners 77,316-184,478
Interest-bearing borrowings 30,0005000
Cash Flow Statement
Item 201720182019-04
Net cash from operating activities -117,388-176,832
Net cash from investing activities -110,957-47,067
Net cash from financing activities 235,179457,601
Net increase in cash 6,834233,702
Purchase of PP&E -111,908-69,604-19,489
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 6.26
First Day OpenHK$ 6.43
First Day Change-4.43%
First Day Volume26029200.0
First Day Turnover165388000.0
Use of Proceeds
1、約30.0%(或153.5百萬港元)將為TAB008的進行中及計劃進行的臨床試驗、注冊備案準備及潛在商業推出(包括銷售及營銷)提供資金; 2、約50.0%(或255.7百萬港元)將為我們研發中的其他在研藥物的進行中及計劃進行的臨床前及臨床試驗、設施擴充、注冊備案準備及潛在商業推出(包括銷售及營銷)提供資金; 3、約15.0%,或76.7百萬港元將用于非項目指定的資本開支; 4、約2.0%(或10.2百萬港元)將為透過內部研究及外部許可以及業務開發合作,持續擴展癌癥及其他潛在治療領域的產品組合提供資金; 5、約3.0%(或15.3百萬港元)將用于我們的營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
Overall Coordinators (2)
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615 Yuanta Securities (Hong Kong) Company Limited CE ABS015
Joint Bookrunners (4)
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615 Yuanta Securities (Hong Kong) Company Limited CE ABS015 China Renaissance Securities (Hong Kong) Limited CE AZX839 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Lead Managers (6)
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 Yuanta Securities (Hong Kong) Company Limited CE ABS015 China Renaissance Securities (Hong Kong) Limited CE AZX839 CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536 LUK FOOK SECURITIES (HK) LIMITED CE ACU547 HEAD & SHOULDERS SECURITIES LIMITED CE AFS455

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Vivo Funds 78,366,820 HKD — 13.29% — 6 months 2020-05-08
2 年兴国际(维京群岛)有限公司 39,182,100 HKD — 6.65% — 6 months 2020-05-08
3 晟德大药厂股份有限公司 39,182,100 HKD — 6.65% — 6 months 2020-05-08

Directors & Management

PositionChinese nameEnglish Name
Chairman付山—
Company Secretary姚朝昶、呂穎一—
No director data available.

Major Shareholders

Major Shareholders & Holdings晟德大藥廠(連同玉晟)為控股股東。緊隨全球發售完成後(假設超額配股權未獲行使),晟德大藥廠持股31.43%、玉晟持股0.85%;Vivo Capital Fund VIII, L.P.及Vivo Capital Surplus Fund VIII, L.P.合計持股17.97%;鈞信持股9.93%;Advantech Capital V持股8.62%。
About this page

This page shows Biodlink-B (01875) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect